Loading page
Loading page
Loading substance route
Effects vary widely by individual, dose, and context.
The cognitive effects of ethylmorphine can be broken down into several components which progressively intensify proportional to dosage. The general head space of codeine is described by many as one of intense euphoria, relaxation, anxiety suppression and pain relief.
The physical effects of ethylmorphine can be broken down into several components which progressively intensify proportional to dosage.
These combinations are considered extremely harmful and should always be avoided. Reactions to these drugs taken in combination are highly unpredictable and have a potential to cause death.
There is considerable risk of physical harm when taking these combinations, they should be avoided where possible.
These combinations are not usually physically harmful, but may produce undesirable effects, such as physical discomfort or overstimulation. Extreme use may cause physical health issues. Synergistic effects may be unpredictable. Care should be taken when choosing to use this combination.
Ethylmorphine has a high potential for abuse and can cause psychological dependence with chronic use. Compulsive redosing is commonly reported, and cravings develop once addiction forms.
Physical dependence develops with chronic use, with withdrawal symptoms occurring upon sudden cessation. Chemical dependence may develop particularly at higher doses.
Ethylmorphine has relatively low toxicity compared to other opioids. However, at least one death has been attributed to oral consumption of ethylmorphine alone without other depressants present. Respiratory depression is the primary mechanism of opioid overdose death.
Long-term chronic use may result in cognitive and affective changes including memory loss and apathy.
Ethylmorphine is a semi-synthetic opioid first synthesized by the pharmaceutical company Merck in 1884. It was developed as a weaker alternative to morphine for therapeutic applications.…
Single Convention on Narcotic Drugs 1961 (Schedule III)
Preparations combining ethylmorphine (10mg) with codeine (10mg), such as Tussipax tablets, are reportedly available without prescription.
Cough syrups containing ethylmorphine (such as Cosylan at 1.7mg/mL and Solvipect comp. at 2.5mg/mL) are available by prescription and commonly used for dry cough treatment.
Available as a prescription medication. Cough preparations containing ethylmorphine (e.g., Cocillana-Etyfin at 2.5mg/mL and Lepheton combination products) require a prescription.
Controlled under the Misuse of Drugs Act 1971 as a Class B substance, the same classification as codeine. However, unlike codeine, no legal pharmaceutical preparations containing ethylmorphine are currently available.
Controlled under Anlage II of the Betäubungsmittelgesetz. Manufacturing, importing, possessing, selling, or transferring without license is prohibited. An exception exists for preparations containing up to 2.5% or 100mg per unit, which may be prescribed using narcotic prescription forms.
Classified as a Schedule II controlled substance under Russian drug control legislation.
Specifically listed as a controlled substance under Verzeichnis A. Medical use is permitted. Certain preparations fall under Verzeichnis C, with some exceptions.
Pure ethylmorphine is Schedule II. Combination products containing no more than 3mg/mL (or 15mg per dosage unit with non-narcotic ingredients) are Schedule III. Preparations with 1mg/mL or less are Schedule V. Despite this scheduling structure paralleling codeine, no ethylmorphine preparations are currently marketed for medical use.
10 sources cited
